Hyemin Jang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8689981/publications.pdf

Version: 2024-02-01

126	1,475	18	30
papers	citations	h-index	g-index
146	146	146	2195
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and APOE Genotype: Importance of Striatal Amyloid. Frontiers in Aging Neuroscience, 2022, 14, 829202.	1.7	9
2	$<$ sup $>$ 18 $<$ $ $ sup $>$ F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in \hat{I}^2 -Amyloid-Negative Amnestic Mild Cognitive Impairment. Yonsei Medical Journal, 2022, 63, 259.	0.9	5
3	Development of prediction models for distinguishable cognitive trajectories in patients with amyloid positive mild cognitive impairment. Neurobiology of Aging, 2022, , .	1.5	2
4	Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease. Life, 2022, 12, 275.	1.1	9
5	Amyloid Positive Hydrocephalus: A Hydrocephalic Variant of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2022, 85, 1467-1479.	1.2	3
6	Intracerebroventricular Administration of Human Umbilical Cord Blood—Derived Mesenchymal Stem Cells Induces Transient Inflammation in a Transgenic Mouse Model and Patients with Alzheimer's Disease. Biomedicines, 2022, 10, 563.	1.4	5
7	Association between Baseline Cognitive Function and Longitudinal Functional Outcome Change after Ischemic Stroke. Dementia and Geriatric Cognitive Disorders, 2022, , 1-7.	0.7	0
8	Written Spelling in Patients with Subcortical Vascular Dementia and Subcortical Vascular Mild Cognitive Impairment. Communication Sciences and Disorders, 2022, 27, 297-312.	0.1	0
9	Cortical neuroanatomical changes related to specific neuropsychological deficits in subcortical vascular cognitive impairment. NeuroImage: Clinical, 2021, 30, 102685.	1.4	9
10	<i>O</i> →GlcNAcylation ameliorates the pathological manifestations of Alzheimer's disease by inhibiting necroptosis. Science Advances, 2021, 7, .	4.7	68
11	Intraspinal Cavity Injection of Human Mesenchymal Stem Cells and Tracking their Migration into the Rat Brain. Journal of Visualized Experiments, 2021, , .	0.2	1
12	Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia. Scientific Reports, 2021, 11, 4168.	1.6	9
13	Cognitive trajectories of patients with focal ß-amyloid deposition. Alzheimer's Research and Therapy, 2021, 13, 48.	3.0	4
14	Amyloid Positivity in the Alzheimer/Subcortical-Vascular Spectrum. Neurology, 2021, 96, e2201-e2211.	1.5	19
15	Prediction of tau accumulation in prodromal Alzheimer's disease using an ensemble machine learning approach. Scientific Reports, 2021, 11, 5706.	1.6	8
16	Machine Learning for the Prediction of Amyloid Positivity in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 80, 143-157.	1,2	11
17	Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. Scientific Reports, 2021, 11, 6954.	1.6	20
18	Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population. Alzheimer's Research and Therapy, 2021, 13, 117.	3.0	7

#	Article	lF	CITATIONS
19	Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 113.	3.0	16
20	Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 321-330.	3.3	1
21	Helicobacter Pylori Infection Is Associated with Neurodegeneration in Cognitively Normal Men. Journal of Alzheimer's Disease, 2021, 82, 1591-1599.	1.2	10
22	Effect of education on functional network edge efficiency in Alzheimer's disease. Scientific Reports, 2021, 11, 17255.	1.6	4
23	Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. Alzheimer's Research and Therapy, 2021, 13, 154.	3.0	57
24	A Case of Early-Onset Alzheimer's Disease Mimicking Schizophrenia in a Patient with Presenilin 1 Mutation (S170P). Journal of Alzheimer's Disease, 2021, 83, 1025-1031.	1.2	1
25	Clinical Characteristic in Primary Progressive Aphasia in Relation to Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2021, 84, 633-645.	1.2	1
26	Thymoma-Associated Paraneoplastic Myositis, Presenting with Rapidly Progressive Muscle		

#	Article	IF	Citations
37	Presynaptic dopaminergic function in early-onset Alzheimer's disease: an FP-CIT image study. Neurobiology of Aging, 2020, 86, 75-80.	1.5	8
38	Reduced forced vital capacity is associated with cerebral small vessel disease burden in cognitively normal individuals. NeuroImage: Clinical, 2020, 25, 102140.	1.4	8
39	Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1971-1983.	3.3	13
40	Clinical significance of focal $ ilde{A}$ Y-amyloid deposition measured by 18F-flutemetamol PET. Alzheimer's Research and Therapy, 2020, 12, 6.	3.0	12
41	A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1938-1948.	3.3	23
42	Differences in neuroimaging features of early- versus late-onset nonfluent/agrammatic primary progressive aphasia. Neurobiology of Aging, 2020, 86, 92-101.	1.5	5
43	The Impact of Amyloid- \hat{l}^2 or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. Journal of Alzheimer's Disease, 2020, 78, 573-585.	1.2	10
44	Disease progression modeling of Alzheimer's disease according to education level. Scientific Reports, 2020, 10, 16808.	1.6	12
45	Strictly Lobar Microbleeds Reflect Amyloid Angiopathy Regardless of Cerebral and Cerebellar Compartments. Stroke, 2020, 51, 3600-3607.	1.0	19
46	Exploring the Potential of Mesenchymal Stem Cell-Based Therapy in Mouse Models of Vascular Cognitive Impairment. International Journal of Molecular Sciences, 2020, 21, 5524.	1.8	2
47	Association between APOE $\hat{l}\mu 2$ and $A\hat{l}^2$ burden in patients with Alzheimer- and vascular-type cognitive impairment. Neurology, 2020, 95, e2354-e2365.	1.5	4
48	Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. Scientific Reports, 2020, 10, 14950.	1.6	24
49	The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. Scientific Reports, 2020, 10, 13583.	1.6	7
50	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.4	35
51	The Effects of Longitudinal White Matter Hyperintensity Change on Cognitive Decline and Cortical Thinning over Three Years. Journal of Clinical Medicine, 2020, 9, 2663.	1.0	17
52	Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments. Scientific Reports, 2020, 10, 19576.	1.6	18
53	The effect of smartphone appâ€based cognitive training on cognition in communityâ€dwelling elderly: A randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e039268.	0.4	0
54	Optical coherence tomography angiography in cognitively impaired patients: Vascular and neurodegenerative perspectives. Alzheimer's and Dementia, 2020, 16, e041738.	0.4	0

#	Article	IF	Citations
55	H. pylori infection is associated with cortical thinning in cognitively normal individuals. Alzheimer's and Dementia, 2020, 16, e044295.	0.4	O
56	Prediction of amyloid \hat{l}^2 PET positivity using machine learning in patients with suspected cerebral amyloid angiopathy markers. Scientific Reports, 2020, 10, 18806.	1.6	6
57	Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases. Alzheimer's Research and Therapy, 2020, 12, 73.	3.0	44
58	Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions. Journal of Alzheimer's Disease, 2020, 76, 281-290.	1.2	13
59	Hearing loss is associated with cortical thinning in cognitively normal older adults. European Journal of Neurology, 2020, 27, 1003-1009.	1.7	18
60	Intrathecal Injection in a Rat Model: A Potential Route to Deliver Human Wharton's Jelly-Derived Mesenchymal Stem Cells into the Brain. International Journal of Molecular Sciences, 2020, 21, 1272.	1.8	22
61	Frontal-executive dysfunction affects dementia conversion in patients with amnestic mild cognitive impairment. Scientific Reports, 2020, 10, 772.	1.6	27
62	Identifying a subtype of Alzheimer's disease characterised by predominant right focal cortical atrophy. Scientific Reports, 2020, 10, 7256.	1.6	5
63	Heterogeneous Disease Progression in a Mouse Model of Vascular Cognitive Impairment. International Journal of Molecular Sciences, 2020, 21, 2820.	1.8	2
64	Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. Journal of Korean Medical Science, 2020, 35, e361.	1.1	13
65	Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. Neurolmage: Clinical, 2019, 24, 101941.	1.4	21
66	Dopa Responsive Parkinsonism in an Early Onset Alzheimer's Disease Patient with a Presenilin 1 Mutation (A434T). Journal of Alzheimer's Disease, 2019, 71, 7-13.	1.2	7
67	Distinct Brain Regions in Physiological and Pathological Brain Aging. Frontiers in Aging Neuroscience, 2019, 11, 147.	1.7	15
68	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report. BMC Neurology, 2019, 19, 211.	0.8	8
69	The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum. Dementia and Neurocognitive Disorders, 2019, 18, 77.	0.4	85
70	Amyloid and cerebrovascular burden divergently influence brain functional network changes over time. Neurology, 2019, 93, e1514-e1525.	1.5	16
71	Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease. Scientific Reports, 2019, 9, 564.	1.6	15
72	Multimodal imaging analyses in patients with genetic and sporadic forms of small vessel disease. Scientific Reports, 2019, 9, 787.	1.6	4

#	Article	IF	CITATIONS
73	Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 69, 213-225.	1.2	O
74	Clinical significance of amyloid \hat{l}^2 positivity in patients with probable cerebral amyloid angiopathy markers. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1287-1298.	3.3	31
75	Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. Scientific Reports, 2019, 9, 1814.	1.6	21
76	Sex-specific relationship of cardiometabolic syndrome with lower cortical thickness. Neurology, 2019, 93, e1045-e1057.	1.5	16
77	Cortical atrophy pattern–based subtyping predicts prognosis of amnestic MCI: an individual-level analysis. Neurobiology of Aging, 2019, 74, 38-45.	1.5	13
78	The Impact of APOE É>4 in Alzheimer's Disease Differs According to Age. Journal of Alzheimer's Disease, 2018, 61, 1377-1385.	1.2	12
79	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 432-442.	3.3	51
80	Prognostic value of amyloid PET scan in normal pressure hydrocephalus. Journal of Neurology, 2018, 265, 63-73.	1.8	28
81	P1â€382: COMPARISON OF AD PATHOLOGIES IN HYPERTENSIVE SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY. Alzheimer's and Dementia, 2018, 14, P445.	0.4	O
82	P1â€386: AMYLOID AND CEREBROVASCULAR BURDEN INFLUENCES ON LONGITUDINAL BRAIN FUNCTIONAL CONNECTIVITY CHANGES IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P448.	0.4	0
83	O1â€1 4â€01: PULMONARY FUNCTION AND CEREBRAL SMALL VESSEL DISEASE AND CORTICAL THINNING IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P256.	0.4	O
84	P2â€319: DISEASE COURSE MODELING OF ALZHEIMER'S DISEASE DEPENDING ON AMYLOID DEPOSITION: AN ACCELERATED LONGITUDINAL DESIGN. Alzheimer's and Dementia, 2018, 14, P804.	0.4	0
85	ICâ€Pâ€121: EFFECTS OF CARDIOMETABOLIC RISK FACTORS ON BRAIN AGING IN THE ELDERLY. Alzheimer's and Dementia, 2018, 14, P102.	0.4	O
86	P1â€407: ALZHEIMER'S DISEASE WITH RIGHT FOCAL CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P459.	0.4	0
87	ICâ€Pâ€078: CLINICAL SIGNIFICANCE OF A/T/N SYSTEM IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT PATIENTS. Alzheimer's and Dementia, 2018, 14, P69.	0.4	O
88	P3â€393: A NOMOGRAM FOR PREDICTING AMYLOID PET POSITIVITY IN AMNESTIC MILD COGNITIVE IMPAIRMENT Alzheimer's and Dementia, 2018, 14, P1248.	0.4	0
89	O1â€14â€03: NATURAL HISTORY OF SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: AN 8.5â€YEAR LONGITU STUDY. Alzheimer's and Dementia, 2018, 14, P258.	IDINAL 0.4	O
90	P1â€483: COGNITIVE RESERVE AND EFFICIENCY NETWORK: IN NORMAL COGNITION, AMNESTIC MCI AND ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P511.	0.4	0

#	Article	IF	CITATIONS
91	P3â€346: CLINICAL SIGNIFICANCE OF AMYLOID BETA POSITIVITY IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY MARKERS. Alzheimer's and Dementia, 2018, 14, P1216.	0.4	O
92	ICâ€Pâ€050: AMYLOID DEPOSITION IN THE SUBCORTICAL REGION PREDICTS COGNITIVE DECLINE. Alzheimer's ar Dementia, 2018, 14, P49.	nd 0.4	0
93	P3â€425: ALZHEIMER'S DEMENTIA CONVERSION IN AMNESTIC MCI ACCORDING TO NEUROPSYCHOLOGICAL PROFILE. Alzheimer's and Dementia, 2018, 14, P1272.	0.4	0
94	A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 66, 681-691.	1.2	38
95	Distinct amyloid distribution patterns in amyloid positive subcortical vascular cognitive impairment. Scientific Reports, 2018, 8, 16178.	1.6	11
96	Trajectories of Physiological Brain Aging and Related Factors in People Aged from 20 to over-80. Journal of Alzheimer's Disease, 2018, 65, 1237-1246.	1.2	17
97	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using ¹⁸ F-AV1451 Positron Emission Tomography Imaging. JAMA Neurology, 2018, 75, 999.	4.5	85
98	Amyloid involvement in subcortical regions predicts cognitive decline. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2368-2376.	3.3	30
99	Social Event Memory Test (SEMT): A Video-based Memory Test for Predicting Amyloid Positivity for Alzheimer's Disease. Scientific Reports, 2018, 8, 10421.	1.6	6
100	Vascular Effects on Depressive Symptoms in Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 65, 597-605.	1.2	6
101	Total MRI Small Vessel Disease Burden Correlates with Cognitive Performance, Cortical Atrophy, and Network Measures in a Memory Clinic Population. Journal of Alzheimer's Disease, 2018, 63, 1485-1497.	1.2	55
102	Prediction Model of Conversion to Dementia Risk in Subjects with Amnestic Mild Cognitive Impairment: A Longitudinal, Multi-Center Clinic-Based Study. Journal of Alzheimer's Disease, 2017, 60, 1579-1587.	1.2	30
103	Diagonal Earlobe Crease is a Visible Sign for Cerebral Small Vessel Disease and Amyloid-β. Scientific Reports, 2017, 7, 13397.	1.6	5
104	Correlations between Gray Matter and White Matter Degeneration in Pure Alzheimer's Disease, Pure Subcortical Vascular Dementia, and Mixed Dementia. Scientific Reports, 2017, 7, 9541.	1.6	39
105	Distinctive Clinical Effects of Haemorrhagic Markers in Cerebral Amyloid Angiopathy. Scientific Reports, 2017, 7, 15984.	1.6	12
106	[P1–224]: ¹⁸ Fâ€AV1451 PET IMAGING IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P329.	0.4	0
107	[P2–406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING ¹⁸ Fâ€₹HK5351 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P786.	0.4	O
108	[P2–407]: PREVALENCE OF AMYLOIDâ€PET POSITIVITY ACCORDING TO AGE AND <i>APOE</i> PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P787.	0.4	0

#	Article	IF	Citations
109	[P2–424]: PROTECTIVE EFFECTS OF EDUCATION ON THKâ€5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT W SUSPECTED NONâ€ALZHEIMER PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P798.	ITH 0.4	O
110	[P3–194]: DIAGONAL EARLOBE CREASE, CEREBRAL SMALL VESSEL DISEASE, AND BETAâ€AMYLOIDOSIS IN COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P1009.	0.4	0
111	[P3–258]: TRAJECTORIES OF COGNITIVE DECLINE IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1042.	0.4	O
112	[P3–337]: THK5351 UPTAKES IN EARLY AND LATE STAGES OF AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1082.	0.4	O
113	[P3–413]: CLINICAL EFFECT OF SMALLâ€VESSEL DISEASE AND WHITE MATTER NETWORK ON DEPRESSION IN PATIENTS WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1124.	0.4	O
114	[P4–169]: COGNITIVE TRAJECTORIES IN PATIENTS WITH NONâ€AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2017, 13, P1326.	0.4	0
115	[P1–423]: THE DEVELOPMENT OF AN ALZHEIMER's DISEASE RISK SCORE BASED ON THE CORTICAL THICKNESS ANALYSES. Alzheimer's and Dementia, 2017, 13, P440.	0.4	O
116	[P1–428]: NONâ€ALCOHOLIC FATTY LIVER DISEASE AND CEREBRAL SMALLâ€VESSEL DISEASE IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P443.	0.4	0
117	[P1–454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THKâ€5351 UPTAKES IN PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P460.	0.4	O
118	[P2â€"318]: RISK SCORE FOR THE PREDICTION OF DEMENTIA RISK IN SUBJECTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL, MULTIâ€CENTER CLINICâ€BASED STUDY. Alzheimer's and Dementia, 2017, 13, P739.	0.4	0
119	[O4–04–03]: SYNERGISTIC EFFECT OF TAU, AMYLOID, AND VASCULAR BURDEN ON COGNITIVE DECLINE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2017, 13, P1235.	0.4	O
120	P4â€196: Clinical Impacts of Cortical Superficial Siderosis in Patients With Clinically Diagnosed Cerebral Amyloid Angiopathy. Alzheimer's and Dementia, 2016, 12, P1099.	0.4	0
121	Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: Data from a nationwide registry in Korea. Journal of Neuroimmunology, 2016, 293, 34-38.	1.1	13
122	Decreased hemoglobin levels, cerebral small-vessel disease, and cortical atrophy: among cognitively normal elderly women and men. International Psychogeriatrics, 2016, 28, 147-156.	0.6	16
123	Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. European Journal of Neurology, 2016, 23, 110-119.	1.7	18
124	Body Mass Index and Mortality Rate in Korean Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 399-406.	1.2	18
125	Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke. Journal of Oncology, 2015, 2015, 1-6.	0.6	33
126	Finding the optimal cutoff value for amyloid \hat{l}^2 positivity using the iterative outlier method and concordance rate. Precision and Future Medicine, 0, , .	0.5	8